Trial reportDiabetes2020
Registry-linked trialOpen access · bronzeAbstract readRandomized Controlled Trial
In one paragraph
Trial report in Diabetes, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05542147 (Physiopathological Study of Genetic Modulation of Cardiovascular Effect of PPAR-Alpha Activation), which is not on this map. Cited by 18 papers.
0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
2.3field-weighted citation impact, top 11% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Physiopathological Study of Genetic Modulation of Cardiovascular Effect of PPAR-Alpha Activation (MAGNETIC-PPARA)
Who cites it
18 citing papers in PubMed, 41 citations in OpenAlex.
- Lipid metabolism in homeostasis and disease.Signal transduction and targeted therapy · 2026Review
- Targeting Cardiac Metabolism in Heart Failure with PPARα Agonists: A Review of Preclinical and Clinical Evidence.Biomedicines · 2025Review
- Decrypting the Possible Mechanistic Role of Fenofibrate in Alzheimer's Disease and Type 2 Diabetes: The Truth and Mystery.Journal of cellular and molecular medicine · 2025Review
- Ling-Gui-Zhu-Gan decoction ameliorates nonalcoholic fatty liver disease via modulating the gut microbiota.Microbiology spectrum · 2024Article
- Hypoglycemic Effects and Quality Marker Screening ofMolecules (Basel, Switzerland) · 2024Article
- Pharmacological Utility of PPAR Modulation for Angiogenesis in Cardiovascular Disease.International journal of molecular sciences · 2023Review
- Precision Medicine in Type 2 Diabetes Mellitus: Utility and Limitations.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Review
- Continuation of fibrate therapy in patients with metabolic syndrome and COVID-19: a beneficial regime worth pursuing.Annals of medicine · 2022Article
- Pharmacogenetics of Cardiovascular Prevention in Diabetes: From Precision Medicine to Identification of Novel Targets.Journal of personalized medicine · 2022Review
- Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD.Diabetes care · 2022Article
- The 2022 American Diabetes Association Meeting.Journal of diabetes · 2022Article
- The Role of High-Density Lipoprotein Cholesterol in 2022.Current atherosclerosis reports · 2022Review
- Lipogenesis inhibitors: therapeutic opportunities and challenges.Nature reviews. Drug discovery · 2022Review
- Improving statin treatment strategies to reduce LDL-cholesterol: factors associated with targets' attainment in subjects with and without type 2 diabetes.Cardiovascular diabetology · 2021Article
- Fenofibrate Protects Cardiomyocytes from Hypoxia/Reperfusion- and High Glucose-Induced Detrimental Effects.PPAR research · 2021Article
- Target Deconvolution of Fenofibrate in Nonalcoholic Fatty Liver Disease Using Bioinformatics Analysis.BioMed research international · 2021Article
- Cholesterol lowering therapies and achievement of targets for primary and secondary cardiovascular prevention in type 2 diabetes: unmet needs in a large population of outpatients at specialist clinics.Cardiovascular diabetology · 2020Article
- Tweeting, tweeting.Journal of diabetes · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 17 institutions in 3 countries.
Mario Luca MorieriResearch Division, Joslin Diabetes Center, Boston, MA.ORCID 0000-0001-6864-0547
Hetal S ShahResearch Division, Joslin Diabetes Center, Boston, MA.ORCID 0000-0002-3685-4572
Jennifer SjaardaMcMaster University and Population Health Research Institute, Hamilton, Ontario, Canada.
Petra A LenziniDepartment of Genetics, Washington University School of Medicine, St. Louis, MO.
Hannah CampbellDepartment of Genetics, Washington University School of Medicine, St. Louis, MO.
Alison A Motsinger-ReifBiostatistics and Computational Biology Branch, National Institute of Environmental Health Sciences, Durham, NC.ORCID 0000-0003-1346-2493
He GaoResearch Division, Joslin Diabetes Center, Boston, MA.
Laura LovatoWake Forest School of Medicine, Winston Salem, NC.
Sabrina PrudenteResearch Unit of Metabolic and Cardiovascular Diseases, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.ORCID 0000-0001-9220-8981
Assunta PandolfiDepartment of Medical, Oral and Biotechnological Sciences, University "G. d'Annunzio," Chieti, Italy.
Marcus G PezzolesiDivision of Nephrology and Hypertension and Diabetes and Metabolism Center, University of Utah, Salt Lake City, UT.ORCID 0000-0002-4093-3783
Ronald J SigalDepartments of Medicine, Cardiac Sciences, and Community Health Sciences, Cumming School of Medicine, Faculties of Medicine and Kinesiology, University of Calgary, Calgary, Alberta, Canada.ORCID 0000-0001-8324-717X
Guillaume ParéMcMaster University and Population Health Research Institute, Hamilton, Ontario, Canada.ORCID 0000-0002-6795-4760
Santica M MarcovinaDepartment of Medicine, University of Washington, and Northwest Lipid Metabolism and Diabetes Research Laboratories, Seattle, WA.
Daniel M RotroffDepartment of Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH.
Elisabetta PatornoDivision of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA.ORCID 0000-0002-8809-9898
Luana MercuriResearch Unit of Metabolic and Cardiovascular Diseases, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
Vincenzo TrischittaResearch Unit of Metabolic and Cardiovascular Diseases, Fondazione IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.ORCID 0000-0003-1174-127X
Emily Y ChewDivision of Epidemiology and Clinical Applications, National Eye Institute, National Institutes of Health, Bethesda, MD.
Peter KraftDepartments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA.
John B BuseDepartment of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC.
Michael J WagnerCenter for Pharmacogenomics and Individualized Therapy, University of North Carolina at Chapel Hill, Chapel Hill, NC.
Sharon CresciDepartment of Genetics, Washington University School of Medicine, St. Louis, MO.
Hertzel C GersteinMcMaster University and Population Health Research Institute, Hamilton, Ontario, Canada.ORCID 0000-0001-8072-2836
Henry N GinsbergIrving Institute for Clinical and Translational Research, Vagelos College of Physicians and Surgeons, Columbia University, New York, NY.ORCID 0000-0002-4103-3592
Josyf C MychaleckyjCenter for Public Health Genomics, University of Virginia, Charlottesville, VA.
Alessandro DoriaResearch Division, Joslin Diabetes Center, Boston, MA alessandro.doria@joslin.harvard.edu.ORCID 0000-0002-3830-4304
Joslin Diabetes Center · USCasa Sollievo della Sofferenza · ITPopulation Health Research Institute · CAWashington University in St. Louis · USUniversity of North Carolina at Chapel Hill · USBrigham and Women's Hospital · USCleveland Clinic · USColumbia University · USHarvard University · USNational Institute of Environmental Health Sciences · USNational Institutes of Health · USUniversity of Calgary · CAUniversity of Chieti-Pescara · ITUniversity of Utah · USUniversity of Virginia · USUniversity of Washington · USWake Forest University · US
Funding
PILOT STUDY--SECRETORY TARGETING IN PANCREATIC B CELLSP30DK036836 · JOSLIN DIABETES CENTER · 1986 to 2025
$12.1MSCCOR in Cardiac Dysfunction and DiseaseP50HL077113 · WASHINGTON UNIVERSITY · 2005 to 2005
$2.8MPREVENTION OF CARDIOVASCULAR DISEASE IN DIABETES MELLITUN01HC095183 · MINNEAPOLIS MEDICAL RESEARCH FDN, INC. · 1999 to 2000
$1.9MPREVENTION OF CARDIOVASCULAR DISEASE IN DIABETES MELLITUN01HC095181 · CASE WESTERN RESERVE UNIVERSITY · 1999 to 2000
$1.8MPREVENTION OF CARDIOVASCULAR DISEASE IN DIABETES MELLITUN01HC095184 · COLUMBIA UNIVERSITY HEALTH SCIENCES · 1999 to 2000
$1.7MPREVENTION OF CARDIOVASCULAR DISEASE IN DIABETES MELLITUN01HC095182 · WAKE FOREST UNIVERSITY · 1999 to 2000
$1.6MPREVENTION OF CARDIOVASCULAR DISEASE IN DIABETES MELLITUS-N01HC95178N01HC095178 · WAKE FOREST UNIVERSITY HEALTH SCIENCES · 1999 to 2005
$1.5MPREVENTION OF CARDIOVASCULAR DISEASE IN DIABETER MELLLITN01HC095180 · UNIVERSITY OF WASHINGTON · 1999 to 2000
$1.5MPREVENTION OF CARDIOVASCULAR DISEASE IN DIABETES MELLITUN01HC095179 · MCMASTER UNIVERSITY · 1999 to 2000
$1.3MACCORD (Action to Control Cardiovascular Risk in Diabetes)ZIAEY000410 · NATIONAL EYE INSTITUTE · 2025 to 2025
$36kNCATS NIH HHS UL1 TR001111NHLBI NIH HHS N01 HC095178NHLBI NIH HHS N01 HC095179NHLBI NIH HHS N01 HC095180NHLBI NIH HHS N01 HC095181NHLBI NIH HHS N01 HC095182NHLBI NIH HHS N01 HC095183NHLBI NIH HHS N01 HC095184NHLBI NIH HHS P50 HL077113NHLBI NIH HHS R01 HL110380NHLBI NIH HHS R01 HL110400NHLBI NIH HHS R01 HL110418NHLBI NIH HHS Y01 HC001010NIDDK NIH HHS P30 DK036836NINR NIH HHS R01 NR013396
Abstract
The cardiovascular benefits of fibrates have been shown to be heterogeneous and to depend on the presence of atherogenic dyslipidemia. We investigated whether genetic variability in the
Indexed as
Polymorphism, Single NucleotideChemokinesDiabetes Mellitus, Type 2DyslipidemiasFemaleFenofibrateGenotypeHumansHypolipidemic AgentsLipidsMaleMiddle AgedPharmacogeneticsPPAR alphaTreatment OutcomeChemokinesFenofibrateHypolipidemic AgentsLipidsPPAR alpha
Identifiers
What Socratic holds
Textmetadata
Read underepoch 390
Registered trials
NCT05542147ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.